ORX Share Price Performance
SEK 27.00
10.52 (63.83%)
28.9% undervalued intrinsic discount
SEK 38.00
Fair Value
Price SEK 27.00
AnalystConsensusTarget SEK 38.00
Fair ValueSEK 38.00
Share Pricen/a
Orexo AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
ORX Community Narratives
AN
Fair Value SEK 38 28.9% undervalued intrinsic discount
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
Key Takeaways Legal settlements and strategic changes stabilize revenue streams, enhancing future planning and financial clarity for Orexo. Advancements in product development and strategic partnerships signal potential growth in revenue and net margins.Read more
32
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 38
28.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-82.38% p.a.
Profit Margin
22.75%
Future PE
2.29kx
Price in 2029
SEK 43.88
Trending Discussion
Recently Updated Narratives
AN
ORX: Higher Required Return Will Still Support Very Large Future P E Multiple
Fair Value: SEK 38 28.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Orexo AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Mar 27, 2026
- -11.48
- 44.23%
- -1,551.15%
- 98.5%
About ORX
- Founded
- 1994
- Employees
- 72
- CEO
- WebsiteView website
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
